Poster Number

015

Session Title

Health and Disease

Document Type

Poster Presentation

Faculty Mentor

Laura Glasscock, Ph.D.; Kathryn Kohl, Ph.D.; and Kunsiri Grubbs, Ph.D.

College

College of Arts and Sciences

Department

Department of Biology

Description

Endothelial cell protein C receptor (EPCR) is expressed in the serum of patients with prostate cancer and in a prostate cancer cell line, PC-3. EPCR is normally expressed by endothelial cells in the blood vessel, where it functions as a co-receptor in the anti-coagulant protein C system. The localization and function of EPCR on endothelial cells is well-documented. Our previous studies have shown that the receptor EPCR interacts with thrombomodulin (TM) on endothelial cells. TM is also expressed by prostate tumor cells in vivo and in vitro, where it regulates proliferation and invasion by these prostate tumor cells. The concentration of TM in patients with prostate cancer is elevated compared to controls. Since EPCR and TM are co-receptors, our goal was to determine the concentration of EPCR in patients with prostate cancer compared to normal controls, and to localize EPCR in PC-3 cells. ELISAs on serum samples from patients with prostate cancer indicated that EPCR concentrations were statistically elevated (82.5 ng/mL to 892.5 ng/mL) compared to control patients (102 ng/mL ± 0.002) (p £ 0.05). Western blotting of cell media and cell lysates from PC-3 cells demonstrated that EPCR is expressed by the prostate cancer epithelial cells. These data provide additional evidence that the anticoagulant protein C system, specifically, EPCR and TM, are involved in prostate cancer progression.

Grant Support?

Supported by the McKay Urology Endowment Fund and by a grant from the Winthrop University Research Council

Included in

Biology Commons

Share

COinS
 
Apr 24th, 12:00 AM

Expression of Endothelial Protein C Receptor in Prostate Cancer

Endothelial cell protein C receptor (EPCR) is expressed in the serum of patients with prostate cancer and in a prostate cancer cell line, PC-3. EPCR is normally expressed by endothelial cells in the blood vessel, where it functions as a co-receptor in the anti-coagulant protein C system. The localization and function of EPCR on endothelial cells is well-documented. Our previous studies have shown that the receptor EPCR interacts with thrombomodulin (TM) on endothelial cells. TM is also expressed by prostate tumor cells in vivo and in vitro, where it regulates proliferation and invasion by these prostate tumor cells. The concentration of TM in patients with prostate cancer is elevated compared to controls. Since EPCR and TM are co-receptors, our goal was to determine the concentration of EPCR in patients with prostate cancer compared to normal controls, and to localize EPCR in PC-3 cells. ELISAs on serum samples from patients with prostate cancer indicated that EPCR concentrations were statistically elevated (82.5 ng/mL to 892.5 ng/mL) compared to control patients (102 ng/mL ± 0.002) (p £ 0.05). Western blotting of cell media and cell lysates from PC-3 cells demonstrated that EPCR is expressed by the prostate cancer epithelial cells. These data provide additional evidence that the anticoagulant protein C system, specifically, EPCR and TM, are involved in prostate cancer progression.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.